1. CURRICULUM VITAE
Erik Torngaard Hansen
Lyngebaekgaards Allé 3,2990 Nivå - Denmark
Born: August 26, 1954
Private: Married to Hanne.One son (1981).
Phone: Mobile +45 2949 6613
Email: Private: erikt.hansen@gmail.com /Job:eth@dat-schaub.dk
KEY COMPETENCIES
__________________________________________________________________________________
Strategic, economic and managementoverview in larger international companies.
Globally initiate,expand and coordinate production ofactive substances and finished goods within pharma
industry.
Similar for protein ingredients within food and feed industries.
Continuous projects allowing for improvements or constant low costof production.
Managementand motivation of employees atall levels in and between different cultures.
Product, process and production developmentand optimization
Innovative technical solutions.
Establish relations with Asian,American,European partners.
PROFESSIONAL EXPERIENCE
_________________________________________________________________________________
2014 - Vice President,Innovation
DC Ingredients+ DAT-Schaub A/S - both companies inthe Danish Crown Group
Responsibility:
Productdevelopment - withincore businessandnew businessareas
NewbusinessandBusinessdevelopment
Productionandlogisticoptimization
Productdevelopmentof innovative new products
– hydrolysed proteins forfeeduse inaquaculture andpet-food.
Newbusinessareawithinfeedingredientmixturesforfurproduction
fromby-products.
Newprocessesforimprovedmicrobiologyonfeedingredientsfrommeatandblood
Productdevelopmentof a large range of innovativenew foodproducts –hydrolysed
proteinsfromdifferentspeciesand -tissue foruse inenergyrichfood.

2. Covering:
Sportsnutrition –improvedrecoveryandalertness/focus.Improvednutritioninfood
forelderly- andsickpeople.
Highenergyandproteinenrichedfoodandmanyotherareas
More innovativeproteinproductsunderintensive development
2005 - Vice President, CSO and COO
DAT-Schaub A/S - company in the Danish Crown group
Turnover: DKK 2,8 billions
Employees:2000
Production: 11 plants in total - thereof DK (3), PL (2), FR (3), PO (2), CN (2)
Responsibility:
Strategy overall
Product development - within core business and new business areas
New business and Business development
Production and logistic optimization
Selection of results within DAT-Schaub from 2005:
Patented process for combining two strings ofcasings into one longer.
Product developmentofinnovative new products – hydrolyzed proteins for feed use
in aquaculture and pet-food.Saving fishmeal with still an improved feed intake.
New business area within feed ingredient mixture for fur production from by-products.
New processes for improved microbiologyon feed ingredients from meatand blood
Product developmentof a large range of innovative new products – hydrolyzed proteins from
different species and -tissue for use in energy rich food.
Covering:
Sports nutrition – improved recovery and alertness/focus.
Improved nutrition in food for elderly- and sick people.
High energy and protein rich food.
and many other areas
More innovative protein products under intensive development.
1980 - 05
1999 - 05
LEO Pharma A/S
Research,develop,produce and sell products within Dermatologyand Critical care.
Turnover: DKK +4 billion
Employees:3000
Products:Daivonex, Daivobet, One Alpha, Fucidin, Innoheop, Heparin,Burinex
Production : 7 plants in total - thereof DK (3), UK(1 closed year end 2004),IRL(2), FR(1)
Executive Vice President – member of LEO Pharmas executive board

3. Member of LEO Pharmas foundation
Duties as member ofthe board
Responsibilities as stated under ” Senior Vice President”
Selection of results within LEOPharma from 1994 until summer 2005
New research and Developmentcomplex- 16.000 m2 in Denmark 220 mil.Kr.
New dry forms manufacturing area – stand alone building – Denmark 100 mil. Kr.
Total upgrade of packing area - Denmark.
New – and upgraded production site for prefilled syringes and tablets including packing - France
Expansion of existing tube manufacturing capacitybulk/filling +80 mil.Tubes/year Dublin Ireland
Maintenance peoples complex- Denmark
Expansion of Fusidin fermentation capacityand purification - Denmark
Introduction of new methods in the biological prod.area -Heparin - Cork/Esbjerg
Expansion of synthesis capacity/pilotplant Denmark – 80mil.Kr.
Optimizing of supplychain – full chain responsibility- including integration ofQC and production
Initial investigation of transfer of production of finished goods/(API) to Korea
Intensive sourcing ofraw materials in China
Training of managers and employees atall levels
Good results ofnegotiation with hourly paid personnel (in DK : SID, KAD and Dansk Metal) – and
with these organizations Continuous optimization and simplification ofwage agreement
Good and accepted results in European employee councils
Increased productivity with fewer employees
Creating good/better/more interesting jobs in all areas
Developmentin Group Variable Cost:
2003 – 2005 : 0,2%
2004 – 2005 : 0%
Developmentemployees:
2002 – 2005 : 10% less to more than 20% increase in turnover
1996 - Senior Vice President of Technology and Production
Overall responsibilityfor LEO Pharmas productions in DK,UK, IRE, FR
Actual 2003 : 165,2 MEUR
Yearly investments:30 – 40 MEUR
Responsible for 1100 employees world wide located in :
Engineer Division,QC, Environment,Purchase,Logistic, Finished products (several
presentations),Synthesis Production,Fermentation,Purification,Extraction of active substance
from organic material.
Construction, expansion and renovation of plants including increased capacityin DK, UK, IRE,
FR
Collective bargaining,wage bargaining,bonus payetc.
Center of Excellence between LEO Pharmas production sites
Bestpractice between LEO Pharmas manufactured production among these QC/QA
Implementation ofselfconduction teams in the production in Denmark (the new and
future way of operating world wide)
1994 - Assistant Director of Technology and Production
Responsible for 450 employees and all production in DK of :
Extraction of Heparin,Fermentation ofFucidin and organic chemical synthesis,final products
(mainlydry forms,liquids,vials and ampoules,later extended)
1989 - Division Manager
Managementof 15 employees
Results:

4. Responsible for synthesis developmentprojectand up scaling of Calcipotriol and its complex14
steps synthesis.(Very active substance)
Responsible for building a plantwith a capacity of 10 kg/year build within budgetand in record
time (The production capacity has since been expanded several times)
Production for the productintroduction in laboratoryand pilotscale.
Later full up scaling to final production in new plant
FDA approval
The substance is the active substance in Daivonex/Daivobet,which still today is LEO-Pharmas
largestproduct.
1980 – Chemical Process Developer
Results:
Chemical process developmentofSultamicillin.A projectwith a combination ofa beta-
lactamase inhibitor Sulbactam with Ampicilin in one molecule.The developmentlead to big scale
production at Pfizer to whom the productwas given in license.
Successfullytransfer ofprocesses.
Implementation ofprocess transfers for Pfizer in UK, USA, IRE.
DevelopmentofPinacidil,Timegadine and VD 2085.
VD 2085 6-beta Bromopenicillanic acid saltwith Pivampicillin
Pinacidil production process is implemented atLEO-Pharmas Irish factory
1978 - 1980 DTU (Danish Technical University)
Assistantteacher,in parallel with studies
Several practical jobs beside
PUBLICATIONS
__________________________________________________________________________________
Journal of Information Recording, 1996: Photochemistryof ergosterol
Acta Crystallographica, 1993: Structure and absolute configuration ofa monohydrate of calcipotriol
Special Publication – Royal Society of Chemistry, 1985: 6-Bromopenicillanic acid sulfoxides:preparation,
isomerization,and synthetic utilization
Synthetic Communications, 1984: Preparation of N-alkyl-N’-4-pyridylthioureas via isolable 4-
pyridylisothiocyanate or via aerial oxidation of 4-pyridyldithiocarbamic acid
Synthetic Communications, 1984: Chlorosulfates as reagents in the synthesis ofcarboxylic acid esters under
phasetransfer conditions
PATENTS
__________________________________________________________________________________
Patent Number P-80602932,tobe completed 2009: A process for joining of pieces of natural casing
Patent Number WO-9926680 A2,June 3, 1999: Container for storing hypodermic syringe before and after use
Patent Number US-5763426,June 9, 1998:Crystalline form of a vitamin D analogue
Patent Number WO-9415912 A1,July 21, 1994: Preparation and formulation ofcalcipotriol hydrate
Patent Number US-5234932,August 10, 1993: Substituted quinolines and leucotriene antagonism treatment
therewith
Patent Number US-5110819,May 5, 1992: Substituted quinolines and medicinal use thereof
Patent Number WO-9103466 A1,March 21, 1991: Preparation and formulation of(aminoalkylphenoxymethyl)
quinoline derivatives as lipoxygenase inhibitors and leukotriene antagonists

5. Patent Number WO-8905294 A, June 15, 1989: New quinolyl methoxy-n-benzyl aniline cpds. – are lipoxygenase
inhibitors and leukotriene antagonists useful for treating e.g. inflammatory conditions and asthma
Patent Number US-4816580,March 28, 1989: Improved method for preparing penicillanic acid derivatives
Patent Number WO-8706230 A1,October 22, 1987:Preparation of penicillanic acid derivatives as ß-lactamase
inhibitors
Patent Number WO-8701371 A1,March 12, 1987: Process for the preparation of 6ß-halopenicillanic acids ß-
lactamase inhibitors by epimerization of6α-halopenicillanic acids
Patent Number GB-2137193 A1, October 3, 1984: Chlorosulfonic acid esters
COMMITEES
__________________________________________________________________________________
2005- DAT-Schaub, France
Member of the Board
2004 - 12 Medialogic A/S (IT Company)
Member of the Board
2002 - VL 68
(Network of executives)
2004 - 05 Procesindustriens Arbejdsgiverforening – Confederation of Danish Industry
2002 - 05 TEC – Teknisk Erhvervsskolecenter
2000 - 05 The LEO-Foundation
The LEO-foundation owns LEOPharma A/S
1999 - 05 Regionalforeningen Hovedstaden – Confederation of Danish Industry
1999 - 03 Panther Plast A/S
(Produces plastic packing for the medical- and food industry)
1997 - 03 LEO Animal Health A/S
1996 - 05 Ballerup Industri- og Erhvervssammenslutning
EDUCATION
___________________________________________________________
2005 – Nov.
2001
2000 - 01
1985 – 99
1980
Leadership around the world,Focus on China/Asia – Shanghai/Singapore - Insead
Leadership in the knowledge societyInsead
DIEU Top Executive Program VL - 68
Specific courses and congresses - several
Courses in USA. FDA Compliance - cGMP
Graduate Engineer with organic chemical synthesis
Master of science
DTU (Danish Technical University)
LANGUAGE
__________________________________________________________________________________
Danish Mother tongue
English Level of Negotiation
French Level of conversation,read

6. German Level of Negotiation
LEISURE-TIME ACTIVITIES
__________________________________________________________
Swimming,diving,cycling, fishing,cooking,wine and travelling